Antipsychotic Effects of Celecoxib Add-On Haloperidol in Schizophrenia: A Randomized Double-Blind Placebo-Controlled Clinical Trial
| Author | Mehran Zarghami | en |
| Author | Nasrin Dodangi | en |
| Author | Paria Azari | en |
| Author | Alireza Khalilian | en |
| Orcid | Mehran Zarghami [0000-0002-7027-0992] | en |
| Orcid | Nasrin Dodangi [0000-0001-6962-6050] | en |
| Orcid | Paria Azari [0000-0002-1468-2693] | en |
| Orcid | Alireza Khalilian [0000-0001-7463-1188] | en |
| Issued Date | 2024-03-31 | en |
| Abstract | Background: Previous studies have indicated abnormalities in the immune system, such as central nervous system inflammation and high levels of activating cytokines in the cerebrospinal fluid of schizophrenic patients. Celecoxib, a modulator of proinflammatory cytokines, as an adjunctive therapy add-on risperidone (a well-established atypical antipsychotic) and amisulpiride (a benzamide antipsychotic), had improved these patients significantly. Objectives: A trial was conducted to evaluate the therapeutic effects of celecoxib add-on haloperidol, a classic antipsychotic that has been reported to have an immunomodulatory effect and mainly affects positive psychotic symptoms in schizophrenia. Methods: In a prospective, double-blind study, after a washout period, 49 patients with schizophrenia were randomly assigned to either 15 - 30 mg/day haloperidol plus 400 mg/day of celecoxib or the same dose of haloperidol plus placebo for 5 weeks. Psychopathology was evaluated via the Positive and Negative Symptoms Scale (PANSS). The data were reported as mean ± standard deviation and frequency. An Independent t-test was carried out when comparing the data of these two groups for each week. The proportion comparison was carried out using the chi-square test. In terms of age, gender, marital and educational state, and duration or severity of disease or psychopathology and subtypes of schizophrenia, there were no significant differences. Results: Over 5 weeks, there was significantly greater improvement in the celecoxib group in scores on the total PANSS and on positive symptoms and general psychopathology subscales ([t = 2.89, P = 0.006], [t = 2.37, P = 0.022], and [t = 3.34, P = 0.002] respectively). Conclusions: Celecoxib is an efficient adjuvant agent in the treatment of patients with schizophrenia. Significant superiority of management with a modulator of proinflammatory cytokine, which balances immune responses over haloperidol alone, reconfirms the immune dysfunction and inflammation hypothesis of schizophrenia. | en |
| DOI | https://doi.org/10.5812/ijpbs-138643 | en |
| Keyword | Celecoxib | en |
| Keyword | COX-2 Inhibitor | en |
| Keyword | Haloperidol | en |
| Keyword | Immune System | en |
| Keyword | Schizophrenia | en |
| Publisher | Brieflands | en |
| Title | Antipsychotic Effects of Celecoxib Add-On Haloperidol in Schizophrenia: A Randomized Double-Blind Placebo-Controlled Clinical Trial | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpbs-138643-publish.pdf
- Size:
- 176.54 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF